PE20130217A1 - Composiciones farmaceuticas y metodos para su elaboracion - Google Patents

Composiciones farmaceuticas y metodos para su elaboracion

Info

Publication number
PE20130217A1
PE20130217A1 PE2012002115A PE2012002115A PE20130217A1 PE 20130217 A1 PE20130217 A1 PE 20130217A1 PE 2012002115 A PE2012002115 A PE 2012002115A PE 2012002115 A PE2012002115 A PE 2012002115A PE 20130217 A1 PE20130217 A1 PE 20130217A1
Authority
PE
Peru
Prior art keywords
composition
amount
preparation
methods
pharmaceutical compositions
Prior art date
Application number
PE2012002115A
Other languages
English (en)
Inventor
Manish K Gupta
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of PE20130217A1 publication Critical patent/PE20130217A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UNA SAL DE ADICION DE ACIDO DE PAZOPANIB EN UNA CANTIDAD DE 10 MG DE BASE LIBRE POR ML DE LA COMPOSICION; B) UNA CICLODEXTRINA MODIFICADA TAL COMO SULFO-BUTIL-ETER DE B-CICLODEXTRINA EN UNA CANTIDAD DE 2.0 A 13.0% EN PESO DE LA COMPOSICION; C) UN AGENTE DE AJUSTE DEL PH QUE PROPORCIONE UN RANGO DE PH DE 3.5 A 5.7 TAL COMO HIDROXIDO DE SODIO, ACIDO CLORHIDRICO Y COMBINACIONES DE LOS MISMOS; D) UN AGENTE DE AJUSTE DE TONICIDAD PARA PROPORCIONAR UNA OSMOLARIDAD DE 200 A 400 mOsm; Y E) AGUA. DICHA COMPOSICION ES UNA COMPOSICION OFTALMICA ESTABLE UTIL EN EL TRATAMIENTO DE DEGENERACION MACULAR RELACIONADA CON LA EDAD
PE2012002115A 2010-05-05 2011-05-05 Composiciones farmaceuticas y metodos para su elaboracion PE20130217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
PE20130217A1 true PE20130217A1 (es) 2013-03-21

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002115A PE20130217A1 (es) 2010-05-05 2011-05-05 Composiciones farmaceuticas y metodos para su elaboracion

Country Status (26)

Country Link
US (3) US20120028918A1 (es)
EP (1) EP2566331B1 (es)
JP (1) JP5835717B2 (es)
KR (1) KR20130071434A (es)
CN (1) CN102970871A (es)
AR (1) AR081364A1 (es)
AU (1) AU2011247995B2 (es)
BR (1) BR112012028291A2 (es)
CA (1) CA2798386A1 (es)
CL (1) CL2012003075A1 (es)
CO (1) CO6640262A2 (es)
CR (1) CR20120556A (es)
DO (1) DOP2012000281A (es)
EA (1) EA201291168A1 (es)
ES (1) ES2519615T3 (es)
HK (1) HK1175947A1 (es)
IL (1) IL222751A0 (es)
MA (1) MA34286B1 (es)
MX (1) MX2012012837A (es)
NZ (1) NZ603411A (es)
PE (1) PE20130217A1 (es)
SG (1) SG185087A1 (es)
TW (1) TW201206908A (es)
UY (1) UY33367A (es)
WO (1) WO2011140343A1 (es)
ZA (1) ZA201208265B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
EP2600930B1 (en) 2010-08-05 2021-02-17 ForSight Vision4, Inc. Injector apparatus for drug delivery
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CA2848385C (en) 2011-09-16 2021-10-26 Forsight Vision4, Inc. Methods and apparatus to exchange a fluid of an implantable device
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
EP3509387B1 (en) * 2012-03-08 2021-07-28 Samsung Electronics Co., Ltd. Method for controlling services in wireless communication system
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP3039424B1 (en) 2013-08-28 2020-07-29 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
JP2017524034A (ja) * 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
US11129900B2 (en) 2014-12-25 2021-09-28 Kyoto University Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
EP3612223A4 (en) * 2017-04-17 2020-04-22 National Institute Of Biological Sciences, Beijing TREATMENT OF MALE SENESCENCE
US11174253B2 (en) 2017-08-02 2021-11-16 Alphala Co., Ltd. Compound and pharmaceutical composition containing the same
HRP20231337T1 (hr) * 2018-06-07 2024-02-16 Pfizer Inc. Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
AU2006320535B2 (en) * 2005-11-29 2010-09-23 Glaxosmithkline Llc Treatment method
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7612102B2 (en) * 2006-04-18 2009-11-03 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions
EP3797775A1 (en) * 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
MX2012000706A (es) * 2009-07-16 2012-06-01 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento.
US20120232102A1 (en) * 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Also Published As

Publication number Publication date
CN102970871A (zh) 2013-03-13
JP2013525501A (ja) 2013-06-20
JP5835717B2 (ja) 2015-12-24
ES2519615T3 (es) 2014-11-07
EA201291168A1 (ru) 2013-06-28
ZA201208265B (en) 2013-07-31
CR20120556A (es) 2013-02-20
NZ603411A (en) 2014-10-31
TW201206908A (en) 2012-02-16
US20150231265A1 (en) 2015-08-20
AU2011247995B2 (en) 2014-07-31
EP2566331A4 (en) 2013-09-18
MA34286B1 (fr) 2013-06-01
MX2012012837A (es) 2013-01-24
DOP2012000281A (es) 2013-05-31
CO6640262A2 (es) 2013-03-22
WO2011140343A1 (en) 2011-11-10
UY33367A (es) 2011-10-31
HK1175947A1 (en) 2013-07-19
KR20130071434A (ko) 2013-06-28
CL2012003075A1 (es) 2013-03-08
IL222751A0 (en) 2012-12-31
AR081364A1 (es) 2012-08-29
EP2566331B1 (en) 2014-09-03
AU2011247995A1 (en) 2012-12-13
US20110281901A1 (en) 2011-11-17
CA2798386A1 (en) 2011-11-10
BR112012028291A2 (pt) 2015-09-15
US20120028918A1 (en) 2012-02-02
EP2566331A1 (en) 2013-03-13
SG185087A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
PE20130217A1 (es) Composiciones farmaceuticas y metodos para su elaboracion
AR125013A2 (es) Método para mejorar la solubilidad de una sustancia que es 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo o una sal del mismo
AR089673A1 (es) Formulacion de premezcla de dexmedetomidina
AR089372A1 (es) Composiciones de cuidado oral
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
AR084285A1 (es) Composiciones inmunogenicas
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014019667A2 (pt) formulação de anticorpo abeta
NI201300068A (es) Moduladores del receptor de glucagón
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
BR112012022469A2 (pt) composição amaciante de tecido concentrada líquida.
AR076932A1 (es) Formulaciones de n-halamina con actividad antimicrobiana aumentada. comprimido desinfectante. metodo para desinfectar.
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112014004732A2 (pt) composto benzotiazolona
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
AR086045A1 (es) Componente de formulacion
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
RS53419B (en) FORMULATIONS OF DEOXYCHOLINIC ACID AND ITS SALTS
AR103719A1 (es) Composición líquida tópica para el lavado intrauterino que contiene melatonina

Legal Events

Date Code Title Description
FC Refusal